Diffuse Bio

Diffuse Bio is an early-stage company operating within the healthcare industry, specifically in drug discovery and delivery. Founded by a team of five, the company is renowned for its pioneering work in AI protein design over the past six years, including the first experimental validation of AI-generated proteins. Their current project involves building a comprehensive AI software platform for molecular design, leveraging breakthroughs in generative AI to design functional proteins. This platform is aimed at developing foundation and generative models for proteins, alongside radically new assays to gather biological data at scale. The team, comprising experimentalists, machine learning research engineers (MLREs), and software engineers (SWEs), has contributed to significant publications in bioRxiv, NatComm, and NeurIPS and has been featured in mainstream media such as the NY Times and NBC. Backed by Y Combinator and several venture capitals like GreatPoint Ventures and Susa Ventures, Diffuse Bio operates both remotely and partly remotely, continuing to lead advancements in AI-powered drug discovery.